Calcio como agente terapéutico en osteoporosis
Calcium as therapeutic agent in osteoporosis
Barra lateral del artículo
PDF
FLIP
Política de acceso abierto
Esta revista proporciona un acceso abierto a su contenido, teniendo en cuenta el principio de que ofrecer al público un acceso libre a las investigaciones ayuda a un mayor intercambio global del conocimiento y no se hace responsable de los contenidos publicados.
Consideraciones éticas
En sus publicaciones la REC contempla las políticas relacionadas con aspectos éticos que se encuentran en World Associationof Medical Editors (WAME)(http://www.wame.org/about/recommendations-on-publication-ethics-policie)
Política sobre derechos de autor
Los autores que publican en la revista se acogen al código de licencia creative commons 4.0 de atribución no comercial sin derivados y compartir igual.
Contenido principal del artículo
Resumen
La osteoporosis es una enfermedad metabólica que produce un hueso cuantitativamente defi ciente, de mala calidad y propenso a fracturas la cual es tratada con Calcio. A pesar de que se conocen los efectos benéfi cos de este elemento, recientes informes lo asocian con complicaciones cardiovasculares. Teniendo en cuenta lo anterior esta revisión buscó plasmar el estado del arte y los conceptos más recientes sobre el uso de Calcio en la osteoporosis así como establecer si el riesgo cardiovascular atribuido a este agente es real. Pensamos particularmente que los benefi cios del calcio como elemento terapéutico para el tratamiento coadyuvante de la osteoporosis exceden los potenciales efectos deletéreos que le asignan. Y que probablemente el presunto riesgo de enfermedad cardiovascular inducida por el calcio sea una falsa alarma y se convierta en otro más de los mitos frecuentes postulados en medicina. Se puede concluir afi rmando que el papel del calcio como elemento mineral es muy importante para el tejido óseo, si bien es cierto que estos agentes se vienen cuestionando en algunos aspectos como seguridad cardiovascular entre otros, definitivamente tanto el calcio como la Vitamina D no son los elementos más potentes en el arsenal terapéutico contra la enfermedad, pero sus défi cits son los más sencillos de identificar y los más fáciles de corregir.
Palabras clave:
Descargas
Detalles del artículo
Referencias (VER)
Cooper C. Epidemiology of Osteoporosis. Osteoporosis Int 1999;2;s2-s8.
Riggs BL, Melton L.J.III. Involutional Osteoporosis. N Engl J Med 1986;314:1676-85.
Guzmán RA. Osteoporosis. In Saludcoop EPS. Guías de manejo en la práctica médica II. Salus Holos Bogotá. 2001;96-99.
Watrous DA, Andrews BS. The metabolism and Immunology of bone. Sem Arthritis Rheum 1989;19:45-65.
Guzmán RA. Osteoporosis tipo 1: Fisiopatología, aspectos inmunológicos, factores de crecimiento. Rev Colomb Reumatol 1994;1:85-89.
Lane NE. Clinical Update. ACR. Sn Francisco 2001.
National Institutes of Health. Osteoporosis. Prevention, Diagnosis, and therapy. Consensus development conference statement. March 27-29;2000.
Notelovitz M. Osteoporosis: Screening, prevention, and management. Fertil Steril 1993;59:707-25.
Melton LJ.III. Evidence base for the physicians, guide to prevention and treatment of osteoporosis. In National OSTEOPOROSIS Foundation. Clinical Symposium for physicians. 2000;3-6.
Guzmán RA. Osteoporosis. Estado del arte. Aventis; vol 1:2003:1-6.
Weaver CM, Heaney RP. Introduction. In Weaver CM, Heany RP. Calcium in human health. Humana Press, 2006;Totowa New Jersey.1-6.
Heany RP. Bone As the calcium nutrient reserve. In Weaver CM, Heany RP. Calcium in human health. Humana Press, 2006;Totowa New Jersey.7-12.
Heaney RP. The calcium economy. In Weaver CM, Heany RP. Calcium in human health. Humana Press, 2006;Totowa New Jersey.14-62.
American Dietetic Association. Position of the American Dietetic Association: the impact of fl uoride on health. J Am Diet Assoc 2001;101:126-32.
Rodhe CM, Deluca H. Bone resorption activity of all-trans retinoic acid is independent of vitamin D in rats. J Nutr 2003;133:777-83.
Johansson S, Melhus H. Vitamin A antagonizes calcium response to vitamin D in man. J Bone Miner Res 2001;16:1899-905.
Promislow JHE, Goodman-Gruen D, Slymen DJ, et al. Retinol intake and bone mineral density in the elderly: the rancho Bernardo study. J Bone Miner Res 2002;17:1349-58.
Silverberg SJ, Shane e, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999;341:1249-55.
Utiger RD. Treatment of primary hyperparathyroidism. N Engl J Med 1999;341:1301-02.
Kassem M, Melton LJ, III, Riggs BL. in Osteoporosis. Marcus R. et al. Academia Press., Sn Diego 1996;691-702.
Mclean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004;350:2042-49.
Van Meurs JBJ, Dhonukshe-Rutten RAM, Pluijm SMF, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004;350:2033-41.
Raisz LG. Homocysteine anf osteoporotic fractures. Culprit or bystander? N Engl J Med 2004;350:2089-90.
Booth SL, Tucker KL, Chen H, et al. Dietary vitamin k intake are associated with hip fracture but no with bone mineral density in elderly men and women. Am J Clin Nutr 2000;71:1201-8.
Shiraki M, Shiraki Y, Aoki Ch, et al. Vitamin k2 effectively prevents fractures and sustain lumbar bone mineral density in Osteoporosis. J Bone Miner Res 2000;15:515-21.
Michaelson K, Lithell H, Vessby B, et al. Serum retinol levels and the risk of fracture. N Engl J Med 2003;348:287-94.
Lips P. Hypervitaminosis A and fractures. N Engl J Med 2003;348:347-49.
Heaney RP. Nutrition and risk for Osteoporosis. In Marcus R, et al. in Osteoporosis. Academic Press., Sn Diego 1996:483-505.
Heaney RP. Calcium. in Bilezikian JP, et al. in Principles of Bone Biology. Academic Press., Sn Diego 1996;1007-18.
Holick MF. Photobiology and noncalcemic actions of Vitamin D. in Bilezikian JP, et al. in Principles of Bone Biology. Academic Press., Sn Diego 1996;447-60.
Awumey EM, Bukoski RD. Cellular functions and fl uxes of calcium. In Weaver CM, Heany RP. Calcium in human health. Humana Press, 2006;Totowa New Jersey.13-38.
Lane NE. Metabolic bone disease. Curr Opin Rheumatol 2007;19:363-64.
Rizzoli R, Boonen S, Brandi ML, et al. The role of calcium and vitamin D in the management of Osteoporosis. Bone 2008;42:246-49. Calcio como agente terapéutico en osteoporosis Roa G. y cols. 103
Watts NB. Postmenopausal Osteoporosis: pathophysiology and treatment. ACR Review Course. Orlando 2003.
Dawson-Hughes B, Harris SS, Dallal GE, et al. Calcium supplement and bone metabolism use in a US medicare health maintenance organization. Osteoporosis Int 2002;13:657-62.
Boonen S, Bischof-Ferrari HA, Cooper C, et al. Adressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int 2006;78:257-70.
Thomas SD, Need AG, Tucker G, et al. Suppression of parathyroid hormone and bone resorption by calcium carbonate and calcium citrate in postmenopausal women. Calcif Int Tissue 2008;83:81-84.
Schett G. Bone formation and destruction in arthritis. ACR Basic Science Symposium. Syllabus. 68th annual scientifi c meeting. San Antonio, 2004.
Utiger RD. The need for more vitamin D. N Engl J Med 1998;338:828-29.
Willet WC, Stampfer MJ. What vitamins should I be taking, doctor? N Engl J Med 2001;345:1819-24.
Guzmán RA. Osteoporosis: inmunología de la enfermedad. Revista ofi cial de la Sociedad Peruana de Climaterio 2003;4:17-22.
Doran PM, Turner RT, Riggs BL, et al. Estrogens and bone health. In Orwoll ES. In Osteoporosis in Men. Academic Press., Sn Diego 1999:275-99.
Reid IR. Menopause. In Favus MJ. In Primer on the metabolic bone diseases and disorders of mineral metabolism. Lippincott Williams& Wilkins.- Fourth Ed Philadelphia 1999 55-57.
Mundy GR. Bone remodeling. In Favus MJ. In Primer on the metabolic bone diseases and disorders of mineral metabolism. Lippincott Williams& Wilkins.- Fourth Ed Philadelphia 1999;30-38.
Manolagas SC, Jilka R. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of Osteoporosis. N Engl J Med 1995;232:305-11.
Portale AA. Blood calcium, phosphorus and magnesium. In Favus MJ. In Primer on the metabolic bone diseases and disorders of mineral metabolism. Lippincott Williams & Wilkins.- Fourth Ed Philadelphia 1999;115-18.
Prince RL, Glendenning P. The physiology and cell biology of calcium transport in relation to the development of osteoporosis. In Orwoll ES, Bliziotes M. in Osteoporosis. Pathophysiology and clinical management. In Humana Press., Totowa 2003;247-64.
Looker AC. Dietary calcium: Recommendations and intake around the world. In Weaver CM, Heany RP. Calcium in human health. Humana Press, 2006;Totowa New Jersey.10-28.
Guzman RA. Nutrición y Tejido óseo: calcico elemental. En Iglesias A. Historia de la vitamina D. Ed. Universidad Simón Bolívar, Barranquilla. 2008;425-40.
Heaney RP. Calcium, bone, and life. In Orwoll ES, Bliziotes M. in Osteoporosis. Pathophysiology and clinical management. In Humana Press., Totowa 2003;265-92.
Heaney RP, Recker RR. Effects of nitrogen, phosphorus, and caffeine on calcium balance in women. J Lab Clin Med 1982;99:46-55.
Dusso As, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289:F8-28.
Holick MF. Resurrection of vitamin D defi ciency and rickets. J Clin Invset 2006;116:2062-72.
Bischoff-Ferrari HA, Giovanucci E, Willet WC, et al. Estimation of optimal serum concentration of 25-hydroxivitamin D for multiples helath outcomes. Am J Clin Nutr 2006;84:18-28.
Lee JM, Smith JR, Philipp PH, et ál. Vitamin D defi ciency un a healthy group of mothers and newborn infants. Clin Pedatr 2007;46:42-44.
Bodnar LM, Simhan HN, Powers RJ, et al. High prevalence of vitamin D insuffi ciency in black and white pregnant women residing in the northern united states and their neonates. J Nutr 2007;137:447-52.
Heaney RP. Protein intake and the calcium economy. J Am Diet Assoc 1993;93:1259-66.
Arnaud CD. Calcium homeostasis: regulatory elements and their integration. Fed Proc 1978;37:2557-60.
Guzmán RA. Nutrición y tejido óseo. Calcio elemental. Rev CES Med 2006;20:65-75.
Molina JF, Betancourt JP, Guzmán RA. Prevención y tratamiento de la osteoporosis. In Molina J, et al. Fundamentos de medicina reumatología. Medellín, CIB, 7ª Ed. 2011.
Reginster JY, Malaise O, Neuprez A, et al. Strontium ranelate in the prevention of osteoporosis fractures. Int J Clin Pract 2007;61:324-28.
Bonne Lye E, Chabadel A, Saltel F, et al. Dual effects of strontiun ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 2008;42:129-38.
Sebastian A, Harris ST, Ottaway JH, et al. Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate. N Engl J Med 1994;330:1776-81.
Kraut JA, Coburn JW. Bone,acid and osteoporosis. N Engl J Med 1994;330:1821-22.
Krall EA, Dawson-Hughes B. Smoking increases bone loss and decreases intestinal calcium absorption. J Bone Miner Res 1999;14:215-20.
Seeman E. Effect of tobacoo and alcohol use on bone. In Osteoporosis. Vol 1. Edited by Marcus R, Feldman D, Kelsey J. Academic Press 2001;770-91.
Francis RM. Calcium and vitamin D in Osteoporosis: Introduction to proceedings. Calcif Tiss Int 2002;70:69-70.
Heaney RP. The importance of calcium intake for lifelong skeletal health. Calcif Tiss Int 2002;70:70-74.
Burckardt P. Calcium and vitamin D in Osteoporosis: supplementation or treatment. Calcif Tiss Int 2002;70:74-77.104 Revista Cuarzo - Fundación Universitaria Juan N. Corpas Vol. 22 No. 2
Schuette SA, Knowles JB. Intestinal absorption of Ca(H2PO4)2 and Ca citrate compared by two methods. Am J Clin Nutr 1988;47:884-88.
Levenson DI, Bockman RS. A review of calcium preparation. Nutrition Rev 1994;52:221-32.
Harvey JA, Zobitz MM, Pak Ch.YC. Dose dependency of calcium absorption: a comparison of calcium carbonate and calcium citrate. J Bone Miner Res 1988;3:253-58.
Broy SB. A Whole patient approach to managing osteoporosis. J Muskuloskel Med 1996;13:15-30.
Scopacasa F, Need AG, Horowitz M, et al. Effects of dose and timing of calcium supplements on bone resorption in early menopause women. Horm Metab Res 2002;34:44-47.
DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80;suppl;1689s-96s.
Holick MH. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006;81:353-73.
Vargo MM. Osteoporosis: Strategies for prevention and treatment. J Muskuloskel Med 1995;12:19-30.
Silverberg SJ, Lindsay R. Postmenopausal Osteoporosis. Med Clin North Am 1987;71:41-55.
Fleisch: Pathophysiology of osteoporosis. Bone Miner 1993;22;S3-6.
Consensus Conference. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
Guzmán RA. Calcio y osteoporosis: papel real. Rev Colomb Reumatol 1998;5:113-15.
Calcium Supplements. Medical Letter, Inc.2000;42:29-31.
Riggs BL, O, Fallon WM, Muhs J, et al. Long-term effects of calcium supplementation on serum parathyroid hormona level, bone turnover, and bone loss in elderly women. J Bone Miner Res 1998;13:168-74.
Talbot JR, Guardo P, Seccia S, et al. Calcium bioavailability and parathyroid hormon acute changes alter oral intake of dairy and nondairy products in healthy volunteers. Osteoporosis Int 1999;10:137-42.
Guillemant J, Le HT, María A, et al. Acute effects of oral calcium load on parathyroid function and n bone resorption in young men. Am J Nephrol 2000;20:48-52.
Saha H, Pietila K, Mustonen J, et al. Acute effects of calcium carbonate and citrate on secondary hyperparathyroidism in chronic renal failure. Am J Nephrol 1991;11:465-69.
Harvey JA, Kenny P, Poindexter J, et al. Superior calcium absorption from calcium citrate than calcium carbonate using external forearm counting. J Am Coll Nutr 1990;9:583-87.
Reginster JY, Denis D, Bartsch V, et al. Acute biochemical variations induced by four different calcium salts an healthy male volunteers. Osteoporosis Int 1993;3:271-75.
Favus Mj, Pak C. Evidence for absorption of ionic calcium and soluble calcium complexes by the duodenum and cecum in the rat. Am J Ther 2001;8:425-31.
Heller HJ, Greer LG, Haynes S, et al. Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women. J Clin Pharmacol 2000;40:1237-44.
Heller HJ, Stewart A, Haynes S, et al. Pharmacokinetics of calcium absorption from two commercial calcium supplements. J Clin Pharmacol 1999;39:1151-54.
Charles P. Calcium absorption and calcium bioavailability. J Inter Med 1992;231:161-68.
Recker R. Calcium absorption and achlorhydria. N Engl J Med 1985;313:70-73.
Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitors use, hip fractures and changes in bone mineral density in postmenopausal women: Results from the women’s health initiative. Arch Intern Med 2010;170:765-71.
Forster M. Proton pump inhibitors and osteoporosis-related fractures. Can Med Assoc J 2009;180:643-44.
Brent-Richards J, Goltzman D. Proton pump inhibitorsÑ balancing the benefi ts and potential fracture risk. CMAJ 2008;179:306-07.
Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179;doi:10.1503/cmaj.071330.
Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitors therapy and risk of hip fractures. JAMA 2006;296:2947-53.
Hunt JN, Johnson C. Relation between gastric secretion of acid and urinary excretion of calcium after oral supplements of calcium. Dig Dis Sci 1983;28:417-21.
Curham GC, Willet WC, Rimm EB, et al. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stone. N Engl J Med 1993;328:833-38.
Lemman Jr J. Composition of the diet and calcium kidney stone. N Engl J Med 1993;328:880-81.
Sakhaee K, Baker S, Zerwekh J, et al. Limited risk of kidney stone formation during long-term calcium citrate supplementation in nonstone forming subjects. J Urol 1994;152:324-27.
Levine BS, Rodman JS, Wienerman S, et al. Effect of calcium citrate supplementation on urinary calcium oxalate saturation in female stone formers: implication for prevention of osteoporosis. Am J Clin Nutr 1994;60:592-96.
Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention on recurrent stones in idiophatic hypercalciuria. N Engl J Med 2002;346:77-84.
Buchinsky DA. Recurrent hypercalciuric nephrolithiasis. Does diet help? N Engl J Med 2002;346:124-25.
Terris S. Calcium plus vitamin D and the risk of fractures. N Engl J Med 2006;354:2285.
Lesser GT. Calcium plus vitamin D and the risk of fractures. N Engl J Med 2006;354:2285-86.
Reid IR., Bolland M. Calcium Supplements and vascular diseases. Climateric 2008;11:280-86. Calcio como agente terapéutico en osteoporosis Roa G. y cols. 105
Sainz J., Van Tornout JM., Loro L., et al. Vitamin-D Receptor gene polymorphisms and bone density in prepubertal american girls of Mexicans descent. N Engl J Med 1997;337:77-82.
Riggs BL. Vitamin D. Receptor genotypes and bone densitiy. N Engl J Med 1997;337:125-27.
Garabedian M. Genetic aspects of osteoporosis. Curr Opin Rheumatol 1995;7:237-39.
Matkcovic VN. Calcium intake and peak bone mass. N Engl J Med 1992;327:119-20.
Johnston CC Jr, Miller JZ, Slemenda Ch W, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992;327:82-87.
Uitterlinden AG, Burguer H, Huang Q, et al. Relation of the alleles of the collagen type 1a 1 gene to bone density and the risk of osteoporosis fractures in postmenopausal women. N Engl J Med 1998;338:1016-21.
Prockop DJ. The genetical trail of osteoporosis. N Engl J Med 1998;338:1061-62.
Matkovic VN. Fifth International Symposium ISO. NOF. Hawai 2002.
Matkovic V. Osteoporosis as a pediatric disease: role of calcium and heredity. J Rheumatol 1992;19:suppl 33;54-59.
Bonjour JP., Rizzoli R. Peak bone mass acquisition. In Orwoll ES., Bliziotes M. in Osteoporosis. Pathophysiology and clinical management. In Humana Press., Totowa 2003;61-82.
Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990;323:878-83.
Reid IR, Ames RW, Evans MC, et al. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993;328:460-64.
Reid I, Ames RW, Evans MC, et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 1995;98:331-35.
Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal Osteoporosis: a comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 1991;325:1189-95.
Homik J, Suárez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. (Cochrane Review). The Cochrane library, Issue 4, 2002. Oxford: update software.
Heaney RP. Calcium in systemic human health. In Weaver CM, Heany RP. Calcium in human health. Humana Press, 2006;Totowa New Jersey.313-17.
Body JJ, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmenoausal osteoporosis: a consensus document by the Belgian bone club. Osteoporosis Int 2010;21:1657-80.
NIH Consensus conference. Optimal calcium intake. NIH consensus development panel on optimal calcium intake. JAMA 1994;272:1942-48.
Lips P, Bouillon R, van Schoor N, et al. Reducing fracture risk with calcium and vitamin D. Clin Endocrinol 2009;doi:10.1111/j.0300-0664.2009.03701.x.
Bischoff Ferrari HA, Dawson-Hughes B, Baron JA, et al. Calcium intake and hip fracture risk in men and women: a Metaanalysis of prospective cohort study and randomized controlled trial. Am J Of Clin Nutr 2007;86:1780-90.
Shea B, Wells G, Cranney A, et al. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis.Endocrine Rev 2002;23:552-59.
Sakhaee K, Bhuket T, Adams-Huet B, et al. Meta-analysis of calcium bioavailability: a comparison of calcium citrate with calcium carbonate. Am J Therap 1999;6:313-21.
Holick MF. In Favos MJ. In Primer on the metabolic bone diseases 1999;92-98.
Tang B, Eslick G, Nowson CA, et al. Use of calcium in combination with vitamin D supplements to prevent fracture and bone loss in peoples aged 50ys and older: a metaanalysis. Lancet 2007;360:657-66.
Sanders KM, Nowson CA, Kotowicks MK, et al. Calcium and bone health. Position Statement for the Australian and New Zealand bone and mineral society, Osteoporosis Australia and the endocrine society of Australia. MJA 2009;190:316-20.
Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metanalysis of randomized controlled trials. JCEM 2007;92:1415-23.
Worensjo E, Pybesk L, Melhos H, et al. Dietary calcium intake and risk on fracture and osteoporosis: Prospevtive longitudinal cohort study. BMJ 2011;342;d1473.
Barron J. Killer Calcium? Heart Health Dietary Suppl 2010. Letter.
Reid IR. Vitamin D and its metabolites in the management of osteoporosis. In Marcus R, et al. in Osteoporosis. Academic Press.,Sn Diego 1996:1169-90.
Christakos S. Vitamin D gene regulation. in Bilezikian JP, et al. in Principles of Bone Biology. Academic Press., Sn Diego 1996;435-46.
Reid IR. Clinical aspects of the use of vitamin D and its metabolites in Osteoporosis. In Orwoll ES, Bliziotes M. in Osteoporosis. Pathophysiology and clinical management. In Humana Press., Totowa 2003;293-308.
Guzmán RA. Aspectos inmunológicos y hueso: inmunopatogenia, inmunogenética. Rev Colomb Osteol Metab Miner 2003;2:514-19.
Holick MF. Vitamin D defi ciency. N Engl J Med 2007;357:266-81.106 Revista Cuarzo - Fundación Universitaria Juan N. Corpas Vol. 22 No. 2
Ikeda K. Mode of action of alfacalcidiol versus plain vitamin D on bone remodeling and bone quality. Abstract book IOF WORLD Congress on Osteoporosis 2002;lisbon.
Morgan SL. Calcium and vitamin D in Osteoporosis. In Osteoporosis. Rheum Dis Clin North Am 2001;1:105-32.
Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000;15:1113-18.
Semba RD, Garret E, Johnson BA, et al. Vitamin D defi ciency among older women with and without disability. Am J Clin Nutr 2000;72:1529-34.
Pfeifer M, Begerow B, Minne HW, et al. Vitamin D status, trunk muscle strength, body sway, falls, and fractures among 237 postmenopausal women with osteoporosis. Exp Clin Endocrinol Diabetes 2001;109:87-92.
Pfeifer M, Begerow B, Minne HW. Vitamin D and muscle function. Osteoporosis Int 2002;13:187-94.
Janssen HCJP, Samson M, Verhaar HJJ. Vitamin D defi ciency, muscle function, and falls in elderly people. Am J Clin Nutr 2002;75:611-15.
Dhesi JK, Moniz C, Close JCT, et al. A rationale for vitamin D prescribing an a falls clinic population. Age Ageing 2002;31:267-71.
Bischof HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003;18:343-51.
Gallagher JC. Physiological interventions to prevent bone loss, falls and non-vertebral fractures in elderly women. (STOP IT study). In abstract books IOF World congress on osteoporosis 2002.
Tinneti ME. Preventing falls in elderly person. et al. N Engl J Med 2003;348:42-49.
Guzmán RA. Osteoporosis: problema médico común. Acta Med Colomb 1994;19:381-83.
Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3 years intervention study. J Bone Miner Res 2004;19:370-78.
Dukas L, Bischoff HA, Lindpaintner LS, et al. Alfacalcidiol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500mg daily. J Am Geriatr Soc 2004;52:230-36.
Pfeifer M, Minne WH. Effects of vitamin D on musculoskeletal health. J Bone Miner Res 2004;19;(suppl 1).WG4;s486.
Gallagher JC, Haynatzky G, Fowler S. Effects of estrogen, calcitriol or the combination of both on falls and non vertebral fractures in elderly women. J Bone Miner Res 2002;17;(suppl 1); abstract F381.
Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. N Engl J Med 1998;338:777-83.
Utiger RD. The need for more vitamin D. N Engl J Med 1998;338:828-29.
Ringe JD, Faber H. Calcium and vitamin D in the prevention and treatment of glucocorticoid-induced osteoporosis. Clin Exper Rheumatol 2000;suppl 21;18:s44-48.
Marcus R, Wong M, Heath H, et al. Antiresortive treatment of postmenopausal osteoporosis: comparison of study design and outcomes in large clinical trials with fractures as an endpoint. Endocrine Rev 2002;23:16-37.
Melton LJ.III., Riggs BL. Postemenopausal Osteoporosis. Treatment. NEJ 1992.
Ingelfi nger JR. Diet and kidney stone. N Engl J Med 2002;346:75-76.
Prince Rl. Diet and the prevention of osteoporotic fractures. N Engl J Med 1997;337:701-02.
Patschan D, Lodenkemper K, Butgereit F. Molecular mechanism of glucocorticoid-induced osteoporosis. Bone 2001;29:498-505.
Dawson-Hughes B. Bone loss accompanying medical therapies. N Engl J Med 2001;345:989-91.
Sen D, Keen RW. Osteoporosis in systemic lupus erythematosus: prevention and treatment. Lupus 2001;10:227-31.
Papadimitropoulos E, Wells G, Shea B, et al. Meta-analysis of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocrine Rev 2002;23:560-69.
Shane E, Addesso V, Namerow PB, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. et al. N Engl J Med 2004;350:767-76.
Lindsay R. Bone loss after cardiac transplantation. N Engl J Med 2004;350:751-53.
Coombes RC, Hall E., Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.N Engl J Med 2004;350:1081-92.
Guzmán RA. Osteoporosis secundaria. Boletín de la Sociedad Peruana de Climaterio 2003. Agosto 3. 1-4.
Homik J, Suárez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced Osteoporosis. (Cochrane Review). In The Cochrane library, Issue 4,2002, Oxford: update software.
Yeap SS, Hosking DJ. Management of corticosteroid-induced osteoporosis. Rheumatology 2002;41:1088-94.
Tyliard MW, Spears GF, Thomson J, et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357-62.
Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637-42.
Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D3 supplementation in elderly women: confi rmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis Int 2002;13:257-64. Calcio como agente terapéutico en osteoporosis Roa G. y cols. 107
Dawson-Hughes B, Harris SS, Krall EA, et al. Effects of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 1997;337;670-76.
Bischop N. Rickets today. Children still need milk and sunshine. N Engl J Med 1999;341:602-05.
Thacher TD, Fischer PR, Pettifor JM, et al. A comparison of calcium, vitamin D or both for nutritional rickets in Nigerian childrens. N Engk J Med 1999;341:563-68.
Arya V, Bhambri R, Godbole M, et al. Vitamin D status and its relationship with bone mineral density in healthy asian indians. Osteoporosis Int 2004;15:56-61.
Orwoll ES. Treatment of osteoporosis in men. Calcif Tiss Int 2004;2:114-19.
Duque G, El Abdaimi K, Henderson JE, et al. Vitamin D Inhibit fas ligand-induced apoptosis in human osteoblast by regulating components of both the mitochondrial and fas-related pathways. Bone 2004;35:57-64.
Kondo T, Kitazawa R, Maeda S, et al. 1 alpha,25 dyhydroxivitamin D3 rapidly regulate the mouse osteoprotegerin gene through dual pathways. J Bone Miner Res 2004;19:1411-19.
Heckman GA, Papaioannou A, Sebaldt RJ, et al. Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. BMC Musculoskelet Disord 2002;1:3-6.
McClung MR, Geusen P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:330-40.
Reid IR, Brown J, Burckhardt P, et al. Intravenous zolendronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.
Guzmán RA. Tratamiento de la osteoporosis diferente a estrógenos: calcio y osteoporosis. Rev Colomb Menop 1998;4:41-44.
Malbanam A, Veronikis IE, Holick MF. Redefi ning vitamin D insuffi ciency. Lancet 1998;351:805-07.
Rosen CJ. Severe hypocalcemia after intravenous bisphosphonates therapy in occult vitamin D defi ciency. N Engl J Med 2003;349:423-26.
Whyte MP, Wenkest D, Clements KL, et al. Bisphosphionatesinduced osteopetrosis. N Engl J Med 2003;349:457-63.
Marini JC. Do Bisphosphonates makes children’s bone better or brittles. N Engl J Med 2003;349:423-26.
Frediani B, Allegri A, Bisogno S, et al. Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis two years of continuous treatmnt. Clin Drugs Invest 1998;15:235-44.
Cauley JA, LaCroix AZ, Wu LL, et al. Serum 25-hydroxivitamin D concentration and risk for hip fractures. Ann Inter Med 2008;149:242-50.
Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 2008;19:399-428.
Trivedi D, Doll R, Kwah K, et al. Effect of four monthly oral vitamin D supplementation on fracture and mortality in men and women living in the community. BMJ 2007;326:469-75.
Sanders KM, Stuart AI, Williamson AJ, et al. Annual high dose oral vitamin D and falls and fractures in older women. JAMA 2010;303:815-22.
Holick MF, Don TC. Vitamin D defi ciency: a worldwide problem with health consequences. Am J Clin Nutr 2008;87:1080-86.
Bikle DD. What is new in vitamin D: 2006-2007. Curr Opin Rheumatol 2007;19:383-88.
Masuyama R, Stockmans I, Torrekens S, et al. Vitamin D recetor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in ostoblast. J Clin Invest 2006;116:3150-59.
Uitterlinden AG, Ralston SH, Brandi ML, et al. The association between common vitamin D receptor gen variations and osteoporosis: a participant level metaanalysis. Ann Intern Med 2006;155:255-64.
Johnson JM, Maher JW, De María EJ, et al. The long-term effects of gastric bypass on metabolism Vitamin D. Ann Surg 2006;243:701-04.
Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to Type 2 diabetes in women. Diabetes Care 2006;29:650-56.
Liu PT, Stenger S, Li H, et al. Tool-like receptor triggering of a vitamin D mediated human antimicrobial response. Science 2006;311:1770-73.
Boscoe FP, Schymura MJ. Solar ultraviolet-B exposure and cancer incidence and mortality in the USA, 1993-2002. BMC Cancer 2006;6:264-71.
Hollis BW, Wagner CL. Nutritional vitamin D status during pregnancy: reasons for concerns. Cmaj 2006;174:1287-90.
Mason JE, Mayne ST, Clinton SK, et al. Vitamin D and preventions of cancer. Ready porprime time. N Engl J Med 2011;364:1492-500.
Wolpowitz D, Gilcherst BA. The vitamin D question: How much do you need and how should you get it? J Am Acad Dermatol 2006;54:301-17.
Wactawski-Wende J, Kutchen JC, Anderson JL, et al. Clacium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-96.
Finkelstein JS. Calcium plus vitamin D for postmenoausal women. Bone apetit. N Engl J Med 2006;354:750-52.
Villar J, Abdel-Almentis L, Merilde M, et al. WHO randomised trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol 2006;194:639-49.
Aventell A, Cook JA, Maclerman GG, et al. Vitamin D supplement to prevent infections: a substudy of a randomized controlled trial in older people. Age Ageing 2007;35:574-77.
Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecifi c musculoskeletal pain. Mayo Clin Proc 2003;78:1463-70. 108 Revista Cuarzo - Fundación Universitaria Juan N. Corpas Vol. 22 No. 2
Broe KE, Chen TC, Weinberg J, et al. A higher dose of vitamin D reduces the rsik of falls in nursing home residents: a randomized, multiple-dose study. J Am Geraitr Soc 2007;5:234-39.
Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006;92:39-48.
Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006;96:252-61.
Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxivitamin D levels and risk of multiple Sclerosis. JAMA 2006;296:2832-38.
Camargo CA, Rifas-Shiman SL, Litonjua AA, et al. Maternal intake of vitamin D during regnancy and risk of recurrent wheeze in children at 3 y of age. Am J Clin Nutr 2007;85:788-95.
Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586-91.
Prockop DJ. Mutation in collagen genes as a cause of connectivetissue diseases. N Engl J Med 1992;326:540-46.m
Morrison NA, Qi JC, Tokita A, et al. Predictor of bone density from vitamin D receptors alleles. Nature 1994;367:284-87.
Hamrick MW. Leptin, Bone mass, and the trifty phenotype. J Bone Miner Res 2004;19:1607-12.
Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in ldl-receptor-related protein 5. N Engl J Med 2002;346:1513-21.
Krane SM. Genetic control of bone remodeling. Insight from a rare disease. N Engl J Med 2002;347:210-12.
Patel ML, Karsenty G. Regulation of bone formation and vision by LRP5. N Engl J Med 2002;346:1572-73.
Klein RF, Allard J, Avnur Z, et al. Regulation of bone mass in mice by the lipoxygenase gene Alox 15. Science 2004;303:229- 32.
Serbian CN. Clues for news therapeutics in osteoporosis. N Engl J Med 2004;350:1902-03.
Guzmán RA. Osteoporosis: inmunología de la enfermedad, aspectos celulares, moleculares y genéticos. Rev Colomb Menop 2003;9:317-28.
Guzmán RA. Osteoporosis: impacto de una antiquísima enfermedad. (Edit). Rev Colomb Reumatol 2000;7:177-80.
Johnston CCJ, Cummings SR, Dawson-Hughes B, et al. Physiciann’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Waschington, DC,1998:1-30.
Goussouss RY, Song L, Dallal G, et al. The effect of calcium intake on the vitamin D requirement. J Bone Miner Res 2004;suppl1;19:s202:SA579.
Kalwarf HJ, Specker BL, Bianchi DC, et al. The effect of calcium supplementation on bone density during lactation and after weaning. N Engl J Med 1997;337:523-28.
Prentice A. Calcium supplementation during breast-feeding. N Engl J Med 1997;337:558-59.
Reid IR, Mason B, Horne A, et al. Effects of calcium supplementation on serum lipid concentration in normal older women: a randomized controlled trial. Am J Med 2002;112:343-47.
Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 1999;340:101-7.
Pence BC. Rol of calcium in colon cancer prevention: experimental and clinical studies. Mutat Res 1993;290:87-95.
Guzmán RA. Distrofi a simpática refl eja. Importancia de su reconocimiento. Rev Colomb Reumatol 1998;5:27-39.
Guzmán RA. Síndrome doloroso complejo regional. Distrofi a simpática Refl eja. Rev Colomb reumatol 2000;7:164-69.
Atkins RM. Complex regional pain sindrome. J Bone Miner Res 2004;3:37-43.
Pipkin FB, Phil D. Risk factor for preeclampsia. N Engl J Med 2001;344:925-26.
Sibai BM, Ewell M, Levine RJ, et al. Risk factor associated with preeclampsia in healthy nulliparous women. Am J Obstet Gynecol 1997;177:1003-10.
Hofmeyr GJ, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. (Cochrane Review). In The Cochrane Library, issue 3, 2002, Oxford. Update software.
Esplin MS, fausset MD, Fraser Al, et al. Paternal and maternal components of the predisposition to preclampsia. N Engl J Med 2001;344:867-72.
Bolland MJ, Barber PA, Dougthy RN, et al. Vascular event in healthy older women receiving calcium supplementation: randomized controlled trial. BMJ 2008;336:262-66.
Bolland MJ, Avenell A, Baron J, et al. Effect of calcium supplementation on risk of myocardial and cardiovascular events: A metaanalysis. BMJ 2010;341:c3691 doi:10.1136/bmj.c3691.
Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcifi cation in young adults with end-stage renal disease who are undergoing dyalisis. N Engl J Med 2000;342:1478-83.
Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcifi cation and phosphates binder choice in incident hemodyalisis patients. Kidney Int 2007;71:438-41.
Fenton A, Panay N. Calcium supplementation: is there a cardiovascular risk? Climateric 2011;14:1-2
Grove M, Cook D. Calcium and heart attacks. Doesn,t aply to most calcium rescritions. (comments). BMJ 2010;341:c5003.
Lewis JR, Calver J, Zhu K, et al. Calcium suplementation and the risks of atheroesclerotic vascular disease in older women: results of a 5 year RCT and a 4.5 year follow up. JBMR 2010. July 7. (Epub ahead of print).
Wang L, Mason JE, Sing Y, et al. Systematic review: Vitamin D and calcium supplementation on revention of cardiovascular events. Ann Intern Med 2010;152:315-23.
Bockman MA. Lecture on Calcium Supplementation. ACR 2011;Chicago. Calcio como agente terapéutico en osteoporosis Roa G. y cols. 109
Referencias adicionales y corregidas, con el texto en la mano, la anterior correspondia a la referencia 252, continuamos ahora
Ciapponi A., Cormick G., Belizan J. Los suplementos de calico. Aumentan el riesgo cardiovascular?. Evid Act Pract Ambul 2015;18:87-88
Cormick G., et al. Calcium supplementation for prevention of primary Hypertension. The Cochrane database of systematic reviews. 2015;6:cd10037
Suplementos de Calcio, Osteoporosis y riesgo cardiovasculart. INFAC 2015. http:/www.osadiketza.net
Lewis JR., et al. The effects of calcium supplementation on verifi ed coronary heart disease hospitalization and death in postmenopausal women: A collaborative Meta-analysis of randomized controlled trials. JBMR 2015;30:165-75.
Montero Saenz A., Formiga F., Pujol FR. Los suplementos de calico y el possible aumento del riesgo cardiovascular. Rev Esp Ger Gerontol 2013;48:doi 10.1016/j.regg 2012.11.008.
Yeserska I., Hernandez Hernadez JL., Olmos Martinez JM., et al. Dyslipiodemia and bone metabolism. A Common bond of the osteoporosis and atherosclerosis?. Rev Osteoporos Metab Miner 2011;3:41-50.
Levie CJ., Lee JH., Milani RV., et al. Vitamin D and cardiovascular disease. Will it live up to its hype?. J Am Coll Cardiol 2011;58:1547-56.
Reid IR., Ames R., Mason B.,et al. Effects of calcium supplementation on lipids, blood pressure, and body composition in healthty older men. A randomized controlled trial. Am J Clin Nutr 2010;91:131-39.
McGreevy C.,. Williams D. Nes insight about vitamin D and cardiovascular diseas. A narrative review. Ann Intern Med 2011;155:820-26.
Lewis JR., Calver J., Zhu K., et al. Calcium supplementation and the risk of atherosclerotic vascular disease in older women: results of a 5-years RCT and a 4.5 years follow-up. JBMR 2011;26:35-41.
Bolland MJ., Grey A., Reid IR. Calcium supplementation and cardiovascular risk. JBMR 2011;26:899
Reid IR., Bolland MJ., Avenell A., et al. Cardiovascular effects of calcium supplementation. Osteoporosis Int 2011;22:1649-58.
Palmer SC., Hayen A., Macaskill P., et al. Serum levels of phosphorus, parathyroid hormone and calcium and risk of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011;305:1119-27.
Crandall CJ., Cauley JA. ACP Journal club. Clcium plus vitamin D was associated with increased cardiovascular risk in women not taking personal calcium Supplements. Ann Intern Med 2011;155:JC2-3 Medline.
Manson JE., Allison MA., Carr JJ., et al. Calcium/Vitamin D supplementation and coronary artery calcification in the women´s health initiative. Menopause 2010;17:683-91.
Geleijnse JM. Vitamin D and the prevention of hypertension and cardiovascular diseases. A review of the current evidence. Am J Hypertens 2011;24:253-62.
Chen JS., Hogan C., Lyubomirsky G., et al. Women with cardiovascular disease have increased risk of osteoporotic fracture. Calcit Tissue Int 2011;88:9-15.
Hsia J., Heiss G., Ren H et al. Calcium/Vitamin D supplementation and cardiovascular events. Circulation 2007;115:846-54.
Bolland M., Grey AS., Reid I. Calcium and cardiovascular risk. Aust Presc 2013;36:5-8.
Li K., Kaaks R., Linseisen J., et al. Association of dietary calcium intake and calcium supplementation with myocardial infraction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European prospective investigation anto cancer and nutrition study. Heart 2012;98:920e925.
Michaelsson K., Melhus H., Warensjo E., et al. Long term calcium intake and rates of all causes and cardiovascular mortality: community based prospective longitudinal cohort study. BMJ 2013;346:f228.
Xiao O., Murphy RA., Hosuton DK., et al. Dietary and supplemental calcium intake and cardiovascular disease mortality: NIH-AARP and healt sudy. JAMA Intern Med February 14 2013. Doi:10.1001/jamainternmed.2013.3283.
Heaney RP. Thinking straight about calcium. N Engl J Med 1993;328:503-05.
WHI. Risk and benefi t of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
Porthouse J, Cockayne S, King C, et al. randomized controlled trial of supplementation with calcium and cholecalciferol for preventions on fractures in primary care. BMJ 2005;330:1003-6.
Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low trauma fractures in elederly peole. Arandomised, placebo, controlled trial. (RECORD study). Lancet 2005;365:1621-28.
Jackson RD, Lacroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-83.
Dawson-Hughes B., N Engl J Med 2006;354.
Willet W, Walz JB, Dawson-Hughes B, et al. Prevention of non vertebral fractures with oral vitamin D and dose dependency. Arch Intern Med 2009;169:551-61.
Ott SM., Chesnut CH. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 1989;110:267-74.
Bolland MJ., Leung W., Tai V., et al. Calcium intake and risk of fracture: Systematic review. BMJ 2015;351:h4580.
Tai V., Leung W., Grey A., et al. Calcium intake and bone mineral density: Systematic review and meta-analysis. BMJ 2015;351:h4183.
Reid I., Bolland MJ., Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 2014;383:146-55 110 Revista Cuarzo - Fundación Universitaria Juan N. Corpas Vol. 22 No. 2
Arabi A., Baddoura R., El-Rassi R., et al. PTH level but not 25(OH) vitamin D level predicts bone loss rates in the elderly. Osteoporosis Int 2012;23:971-80.
Bischoff-Ferrari HA., Kiel DP., Dawson-Hughes B., et al. Dietary calcium and serum 25-hydroxyvitamin D sattus in relation to BMD among US adults. JBMR 2009;24:935-42.
Avenell A., Gillespie WJ., Gullespie LD., et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and postmenopausal Isteoporosis. Cochrane Database Syst Rev 2009;2.
Baily RL., Dodd KW., Goldman JA., et al. Estimation of total usual calcium and vitamin D intakes in the United States. J Nutr 2010;140:817-22.
Lips P., van Schoor NM. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab 2011;25:585-91.
Holick MF., Binkley NC., Bischoff-Ferrari HA., et al. Evaluation, treatment, and prevention of vitamin D defi ciency: an Endocrine Society Clinical practice guidelines. JCEM 2011;96:1911-30.
Chung M., Lee J., Terasawa T., et al. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the UD preventive service task force. Ann Intern Med 2011;155:827-38.
Jorde R., Sneve M., Torjesen PSA., et al. No signifi cant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year. Nutr J 2010;9:1.
Verschueren SMP., Bogaerts A., Delecluse C., et al. The effects of whole-body vibration training and vitamin D supplementation on muscle strength, muscle mass, and bone density in institutionalized elderly women: a 6 month randomized, controlled trial.JBMR 2011;26:42-49.
Grimnes G., Joakimsen R., Figenschau Y., et al. The effect of high-dose vitamin D on bone mineral density and bone turnovers markers in postmenopausal women with low bone mass. A randomized controlled 1-year trial. Osteoporosis Int 2012;23:201-11.
Nieves J., Coaman F., Grubert E., et al. Skeletal effects of vitamin D supplementation in postmenopausal black women. Calcif Tisue Int 2012;91:316-24.
Sanders KM., Stuart AL., Williamson EJ., et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010;303:1815-22.
Maxmen A. Te vitamin D-Lemma. Nature 2011;475:23-25.
Bischoff Ferrari HA., Willet WC., Orav EJ., et al. A pooled analysis of vitamin D doses requirements for fracture prevention. N Engl J Med 2012;367:40-49.
Murad MH., Elamin KB., Abu Elnour NO., et al. The effect of vitamin D on falls: a systematic review and meta-analysis. JCEM 2011;96:2997-3006.
Rosen CJ. Vitamin D supplementation: bones of contention. Lancet 2014;383:108-110.
Leslie W., Morin SN., Lix L. Rate of bone density changes does not enhance fracture prediction in routine clinical practice. JCEM 2012;97:1211-18.
Committee to review dietary refrence intake for vitamin D and calcium. Dietary reference intakes for calcium and vitamin D. Waschington, DC: National Academies Press, 2011.
Busse B., Bale HA., Zimmermann EA., et al. Vitamin D defi ciency induces early signs of aging in human bone increasing the risk of fracture. Sci Transl Med 2013;5:193ra88.
Bischoff-Ferrari HA, Giovannuci E, Willet WC, et al. Estimation of optimal serum concentrations of 25-hydroxivitamin D for multilles health outcomes. Am J Clin Nutr 2006;84:18-28.
Dawson-Hughes B, Heaney R, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporosis Int 2005;16:713-16.
Solomon CG, Dluhy RG. Rethinking postmenopausal hormone therapy. N Engl J Med 2003;348:579-81.
Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-51.
Grady D, Herrington DM, Bitnner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. 8HERS II). JAMA 2002;288:49-57.
Herrington DM, Reboussim DM, Brosnihah B, et al. Effects of estrogen plus progestin in healthy postmenopausal women: principal results from the women health initiative randomized controlled trial. JAMA 2002;288:321-23.
Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health related quality of life. N Engl J Med 2003;348:1839-54.
Grady D. Postmenopausal hormones: Therapy for symptoms only. N Engl J Med 2003;348:1835-37.
Shuzu M, SebastianS, Takayama K, et al. Estrogen excess assiociated with novel gain of function mutation affecting the aromatase gen. N Engl J Med 2003;348:1855-65.
Manson JE, Asia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary diseases. N Engl J Med 2003;349:522-34.
Herrington DM, Howard ID. From presumed benefi t to potential harm. Hormones therapies and heart disease. N Engl J Med 2003;349:519-20.
Bailor J. Hormone Therapy replacement and cardiovascular disease. N Engl J Med 2003;349:521-23.
Riggs BL, Hartmann LC. Selective estrogen-receptor modulators. Mechanism of action and application to clinical practice. N Engl J Med 2003;348:618-29.
Barham M. Selective estrogen receptor modulators. N Engl J Med 2003;348:2259-61.( letter).
Shea B, Wells G, Cranney A, et al. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocrine Rev 2002;23:552-59. Calcio como agente terapéutico en osteoporosis Roa G. y cols. 111
Cranney A, Simon LS, Tugwell P, et al. Postmenopausal Osteoporosis. Evidence-based Rheumatology. BMJ 2004;8-10.
Guzmán RA. Agentes anabólicos óseos: utilidad terapeética. Rev Colomb Reumatol 2001;8:449-58.
Neer RM, Arnaud C, Zancheta JR, et al. Effect of parathyroid hormone,(1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. et al. N Engl J Med 2004;350:459-68.
El-Hajj Fulehian G. Strontium ranelate. A novel therapy for Osteoporosis or a permutation of the same? N Engl J Med 2004;350:504-06.
Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. et al. N Engl J Med 2003;349:1207-15.
Filkestein JS, Hayes A, MSN, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-26.
Khosla S. Parathyroid hormone plus alendronate. A combination that does not add up. N Engl J Med 2003;349:1277-79.
Bone HG, Hosking D, Devogelaer JP, et al. Ten years’s experience with alendronate for osteoporosis in postmenopausal women. et al. N Engl J Med 2004;350:1189-99.
Strewler GJ. Decimal point. Osteoporosis therapy at the 10-year mark N Engl J Med 2004;350:1172-74.
Pors Nielsen S.- The biological role of strontium. Bone 2004;35:583-88.
Recker R, Ensrud K, Diem S, et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Res 2004;suppl 1;19:s45:1173.
Black D, Schwartz A, Ensrud K, et al. A 5 year randomized trial of the long-term effi cacy and safety of alendronate: The FIT long term extension (FLEX). J Bone Miner Res 2004;suppl1;s45:1174.
Boonen S, McClung MR, Eastell R, et al. Safety and effi cacy of risedronate in reducing fracture risk in ostyeoporotic women aged 80 and older: implications for the use of antiresorptives in the old ald oldest old. J Am Geriatr Soc 2004;52:1832-39.
Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;Oct 14.1-15.
Guzmán RA. Bifosfonatos en osteoporosis. ActoNews 2004;1:(abril)1-4.
Reszka AA, Rodan GA. The mechanism of action of nitrogencontaining bisphosphonates. In Orwoll ES., Bliziotes M. in Osteoporosis. Pathophysiology and clinical management. In Humana Press. Totowa 2003.447-58.
Cadwell CR, Abnett CC, Centorelli M, et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010;304:657-63.
Black DM, Kelly M, Genant HK, et al. Bisphophonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362: 1761-71.
Shane E. Evolving data about subtrochanteric fractures and bishosphonates. N Engl J Med 2010;362:1825-27.
Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diahysis in ostmenoausal women taking alendronate. N Emgl J Med 2008;358:1304-6.
Pallais JC, Kifor O, Chen YB, et al. Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor. N Engl J Med 2004;351:362-69.
Stewart AF. Translational implication of the parathyroid calcium receptor. N Engl J Med 2004;351:324-26.
Tsai JN., Uihlein AV., Lee H., et al. Teriparatide and denosumab, alone o combined, in women with postmenopausal osteoporosis: The DATA study, randomized trial. Lancet 2013;382:50-56
Eastell R., Walsh JS. Is it time to combine Osteoporosis therapies?. Lancet 2013;382:5-7.
Leder BZ., Tsai JN., Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis(The DATA Extension study): a randomized controlled trial. JCEM Online February 11 , 2014.
Reginster JY. Cardiac concerns associated with Strontium ranelate. Expert Opin Drug Saf 2014;13:1209-13.
European Medicines agency Good pharmacovigilance practices. www.ema.europa.eu/ema/index.jsp 000345. 20 march 2014.
Reginster JY., Badurski J., Bellamy N. Effi cacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomized, placebo-controlled trial. Ann Rheum Dis 2013;72:179-86.
Abrahamsen B., Grove EL., Vestergaard P. Nationwide registrybased analysis of cardiovascular risk-factors and adverse outcomes in patients treated with strontium ranelate. Osteoporosis Int 2014;25:757-62.
Svanstrom H., Pasternak B., Hviid A. Use of strontium ranelate and risk of acute coronary syndrome: cohort study. Ann Rheum Dis 2014;73:1037-43.
Donneau AF., Regisnter JY. Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice. Osteoporosis Int 2014;25:397-98.
Guzman RA., Rodriguez W., Cordoba J., et al. Experiencia con Ranelato de Stroncio en Osteoporosis y Osteoartritis y eventos adversos cardiovasculares. 2016. (Personal communication, in Press).
Honig S. Osteoporosis: New Treatments and updates. Bull NYU Joint Dis 2011;69:253-56.112 Revista Cuarzo - Fundación Universitaria Juan N. Corpas Vol. 22 No. 2
McClung MR. Denosumab. In Rosen CJ. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th Ed, ASBMR. Wiley-Blackwell, Iowa, 2013: 420-427.
Rizzoli R. Strotium Ranelate in the prevention of osteoporotic fractures. In Rosen CJ. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th Ed, ASBMR. Wiley-Blackwell, Iowa, 2013: 437.443.
Wah Ng K., Martin TJ. Future Therapies of Osteoporosis. In Rosen CJ. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th Ed, ASBMR. Wiley-Blackwell, Iowa, 2013: 461-467.
McClung MR., Grauer A., Boonen S., et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370:412-20.
Cosman F., Crittenden DB., Adachi JD., et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016;375:1532-43.
Rosen CJ., Ingelfi nger JR. Building better bones with biologics. A new approach to osteoporosis?. N Engl J Med 2016;375:1583-84.
Going S, Lohman T, Houtkooper L, et al. Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy. Osteoporosis Int 2003;14:637-43.
Bouillon R, Norman AW, Lis P. Vitamin D defi ciency. N Engl J Med 2007;357:1980-81.
Holick MD. Vitamin D defi ciency. N Engl J Med 2007;357:1982.
Vieth R, Bischoff-Ferrari HA, Boucher BJ, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 2007;85:649-50.
Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586-91.
Devine A, Dhaliwal SS, Dick IM, et al. Physical activity and calcium consumption are important determinants of lower limb bone mass in.
Sohl E., Heymans MK., de Jong RT., et al. Prediction of Vitamin D defi ciency by simple patients characteristics. Am J Nutr 2014;99:1089-96.
Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008;135:825-37.
Gonzales D., Zuñiga C., Kattah W., et al. Insufi ciencia de Vitamina D en pacientes adultos con baja masa osea y Osteoporosis en la Fundacion Santa Fe de Bogota 2008-09. Rev Colomb Reumatol 2010;17:212-18.
Molina JF., et al. Niveles de 25 hidroxivitamina D y su correlacion clinica con diferentes variables metabolicas y cardiovasculares en una poblacion de mujeres postmenopausicas. Acta Med Colomb 2011;36:18-23.
Guzman RA., Piñeros LG., Teheran A., et al. Prevalencia de hipovitaminosis D y su relación con el consumo de calcio en población adulta de Bogota en el 2015.DiCaVitD. CINVEST Noviembre 2015.
Guzman RA., Piñeros LG., Teheran A., et al. Hypovitaminosis D and calcium intake of adult population in Bogota. (DiCaVitD. ) Ann Rheum Dis 2016;in Press. EULAR 16-3330.
Manson JE., Brannon PM., Rosen CJ., et al. Vitamin D Defi ciency. Is there really a pandemic?. N Engl J Med 2016;375:1817-20.
Haney EM, Warden SJ. Skeletal effects of serotonin transporter inhibition: evidence from clinical studies. J Musculoskelt Neuronal Interact 2008;8:133-45.
Rosen CJ. Serotonin rising. The bone, brain, bowel connection. N Engl J Med 2009;360:957-59.
Honing S. Osteoporosis: New treatment and updates. Bull NYU Joint Dis 2011;69:253-56.
Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenoausal women with low bone mineral density: Three-year continued theray and resolution of effect. JBMR 2011;26:242-51.
Bauer DC. Discontinuation of odanacatib and other osteoporosis treatments: Here today and gone tomorrow. JBMR 2011;26:239-41.
Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenoausal women with osteoporosis. N Engl J Med 2009;361:756-65.
Rizzoli R. Bishosphonates for postmenoausal osteoporosis: are they all the same? QJM 2011;104:281-300.
Adler RA, Gill RS. Clinical utility of denosumab for vtreatment of bone loss in men and women. Clin Interv Aging 2011;6:119-24.
DUFADatl.com 2012. February.
Modern Medicine 2012;February.
Vasquez-Awad D., Guzman RA. Denosumab. En Osteoporosis: Enfoque Clinico y tratamiento. 2a Ed, Kimpres Ltda, Bogota. 2012; 651-60.
Cummings SR., San Martin J., McClung MR., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
Pullen LC. Study Target Osteoclast receptor to inhibit osteoclastogenesis. Rheumatologist 2016;Feb 15.
Haywood J., Qi J., Chen CC., et al. Structural basis of collagen recognition by human osteoclast-associated receptor and design of osteoclastogenesis inhibitors. Proc Natl Acad Sci USA 2016 Jan 7.pii:2011522572.
Lips P, Hosking D, Lipuner K, et al. The revalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med 2006;260:245-54.
Abrahamsen B, Sahoti O. Do calcium plus vitamin D Supplements increase cardiovascular risk?. BMJ 2011;342:d2080.
Vasquez-Awad D., Guzman RA., Rueda C., et al. Consenso Colombiano de Vitamina D en Osteoporosis. Menopause meeting Prague. In Press 2016.
